Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study (original) (raw)
A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
Kim Papp
British Journal of Dermatology, 2013
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, Phase 3 trials
Pedro Miranda
The British journal of dermatology, 2015
View PDFchevron_right
Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
Stefania Madonna
Journal of Immunology Research
View PDFchevron_right
The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
Tsen-fang Tsai
Journal of dermatological science, 2017
View PDFchevron_right
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial
Kim Papp
The Journal of dermatology, 2017
View PDFchevron_right
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
Kim Papp
BMC dermatology, 2016
View PDFchevron_right
Tofacitinib for the treatment of moderate-to-severe psoriasis
Maria Sole Chimenti
Expert Review of Clinical Immunology, 2015
View PDFchevron_right
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
Fernando Valenzuela
Lancet, 2015
View PDFchevron_right
Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
Kim Papp
CPT: Pharmacometrics & Systems Pharmacology, 2013
View PDFchevron_right
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Valderilio F Azevedo
The New England journal of medicine, 2017
View PDFchevron_right
Do Patients and Physicians Agree in Their Assessment of the Severity of Psoriasis ? Insights from Tofacitinib Phase 3 Clinical Trials
Lotus Mallbris
2015
View PDFchevron_right
A randomized phase 2b trial of baricitinib, an oral Janus kinase ( JAK ) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis
Kim Papp
British Journal of Dermatology, 2016
View PDFchevron_right
Tofacitinib in patients with moderate to severe chronic plaque psoriasis: 2-year efficacy and safety in an open-label long-term extension study
Tsen-fang Tsai
Journal of the American Academy of Dermatology, 2016
View PDFchevron_right
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies
Kim Papp
Journal of the European Academy of Dermatology and Venereology, 2020
View PDFchevron_right
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
Mary Bachinsky
British Journal of Dermatology, 2015
View PDFchevron_right
Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study
Jocelyne Papacharalambous
Journal of the European Academy of Dermatology and Venereology, 2016
View PDFchevron_right
IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood
Mayte Suarez-Farinas
The Journal of investigative dermatology, 2014
View PDFchevron_right
A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
Joseph Cappelleri
BMC Dermatology
View PDFchevron_right
JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
Leeyen Hsu
Journal of Immunology Research, 2014
View PDFchevron_right
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment
Mayte Suarez-Farinas
Journal of Investigative Dermatology, 2017
View PDFchevron_right
Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience
Tsen-fang Tsai
Dermatology and Therapy
View PDFchevron_right
Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions
James Krueger
Journal of Investigative Dermatology, 2010
View PDFchevron_right
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
Naresh Punwani
Journal of the American Academy of Dermatology, 2012
View PDFchevron_right
Psoriasis: A STAT3-Centric View
Enzo Calautti
International Journal of Molecular Sciences, 2018
View PDFchevron_right
Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials
Valderilio F Azevedo
Clinical Rheumatology, 2021
View PDFchevron_right
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Oliver Fitzgerald
Rheumatology and therapy, 2020
View PDFchevron_right
Immunohistochemical study of janus kinase 1/signal transducer and activator of transcription 3 in psoriasis vulgaris
Rehab Samaka
Clinical, Cosmetic and Investigational Dermatology, 2019
View PDFchevron_right
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
Huifeng Yun
Drug Safety, 2020
View PDFchevron_right
Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
Ana-maria Orbai
BMC Rheumatology
View PDFchevron_right